Localized chromophobe carcinomas treated by nephron-spanng surgery have excellent oncologic outcomes
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | Localized chromophobe carcinomas treated by nephron-spanng surgery have excellent oncologic outcomes |
Type de publication | Journal Article |
Year of Publication | 2017 |
Auteurs | Bigot P, Bernhard J-C, Flamand V, Gill I, Verhoest G, Beauval JBaptiste, Nouhaud FXavier, Suer E, Ploussard G, Francois J, Rigaud J, Baco E, Larre S, Sebe P, Koutlidis N, Descazeaud A, Eto M, Doerfler A, Roupret M, Vuong NSon, Reix B, Matsugasumi T, Bakri AEl, Albiges L, Soulie M, Patard J-J, Mejean A, Bensalah K, CCAFU |
Journal | UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS |
Volume | 35 |
Date Published | JAN |
Type of Article | Article |
ISSN | 1078-1439 |
Mots-clés | Chromophobe renal carcinoma, Nephron-sparing surgery, Oncologic outcomes |
Résumé | Objective: To evaluate the oncologic outcomes of nephron-sparing surgery (NSS) for localized chromophobe renal cell carcinoma (cRCC). Material and methods: We performed a multicenter international study involving the French Network for Research on Kidney Cancer (UroCCR) and 5 international teams. Data from 808 patients treated with NSS between 2004 and 2014 for non clear cell RCCs were analyzed. Results: We included 234 patients with cRCC. There were 123 (52.6%) females. Median age was 61 (23-88) years. Median tumor size was 3 (1-11) cm. A positive surgical margin was identified in 14 specimens (6%). Pathologic stages were T1, T2, and T3a in 202 (86.3%), 9 (3.8%), and 23 (9.8%) cases, respectively. After a mean follow-up of 46.6 36 months, 2 (0.8%) patients experienced a local recurrence. No patient had metastatic progression, and no patient died from cancer. Three -years estimated cancer -free survival and cancer -specific survival were 99.1% and 100%, respectively. Conclusion: Oncological results of NSS for localized cRCC are excellent. In this series, only 2 patients had a local recurrence, and no patient had metastatic progression or died from cancer. (C) 2017 Elsevier Inc. All rights reserved. |
DOI | 10.1016/j.urolonc.2016.08.012 |